Lori A. Leslie, MD

Lori A. Leslie, MD, is director of the Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs at John Theurer Cancer Center at Hackensack Meridian Health and an assistant professor at the Hackensack Meridian School of Medicine.

Articles

Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma

December 9th 2025

Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.

Dr Leslie on the Efficacy of Axi-Cel in Relapsed/Refractory MZL

January 31st 2025

Lori A. Leslie, MD, discusses efficacy data from the phase 2 ZUMA-5 trial evaluating axi-cel in relapsed/refractory marginal zone lymphoma.

Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL

December 23rd 2024

Meta: Lori A Leslie, MD, discusses 5-year follow-up data from the ZUMA-5 trial evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr Leslie on the Utility of Axi-cel in High-Risk LBCL

May 22nd 2024

Lori A. Leslie, MD, discusses the utility of treatment with axi-cel through the lens of the ZUMA-7 trial in large B-cell lymphoma.

Unmet Needs and Challenges in Lymphoma

April 2nd 2024

Looking to the future, Lori A. Leslie, MD, offers closing thoughts on unmet needs and potential improvements in the lymphoma treatment space.

CAR T-Cell Therapy: Managing Adverse Events and Assessing Patient Response in Lymphoma

April 2nd 2024

Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra.

Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

March 26th 2024

Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.

Recent Data on Axi-Cel in Lymphoma

March 26th 2024

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

Subcutaneous Mosunetuzumab in Follicular Lymphoma

March 19th 2024

A hematologist-oncologist discusses a recent abstract looking at subcutaneous mosunetuzumab in the first line for patients with follicular lymphoma.

The Evolving Lymphoma Treatment Landscape

March 19th 2024

Lori A. Leslie, MD, a specialist in lymphoma, provides an overview of recent changes in the overall treatment landscape.

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

January 2nd 2024

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.

Dr Leslie on Outpatient CAR T-Cell Therapy Programs for Hematologic Malignancies

November 23rd 2023

Lori A. Leslie, MD, discusses the benefits of implementing CAR T-cell therapy programs for patients with hematologic malignancies and highlights the successes with administering CAR T-cell therapy that JTCC has experienced.

Dr. Leslie on the 3-Year Follow-Up of the ZUMA-5 Trial in R/R iNHL

December 19th 2022

Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Unmet Needs and Future Directions in Care for Relapsed/Refractory FL

December 6th 2022

Closing out her discussion on novel therapy for relapsed/refractory follicular lymphoma, Lori Leslie, MD, highlights unmet needs and considers future evolutions in the treatment paradigm.

Practical Selection of Novel Therapy for Relapsed/Refractory Follicular Lymphoma

December 6th 2022

Insight to the factors that help select optimal third-line treatment for patients with follicular lymphoma in the context of available novel therapies.

Novel Third-Line Therapies for Relapsed/Refractory Follicular Lymphoma

November 30th 2022

A comprehensive overview of the third-line treatment armamentarium for patients with relapsed/refractory follicular lymphoma.

Relapsed/Refractory Follicular Lymphoma: Sequencing Through Multiple Lines of Therapy

November 30th 2022

Key opinion leader Lori Leslie, MD, sheds light on the optimal sequencing of therapy throughout multiple lines of follicular lymphoma.

Assessing Response to Therapy and High-Risk Disease in Follicular Lymphoma

November 23rd 2022

An expert’s perspective on assessing response to therapy in follicular lymphoma and the parameters used to identify high-risk disease.

Overview on Follicular Lymphoma and A Patient Case of Relapsed/Refractory Disease

November 23rd 2022

Expert hematologist-oncologist Lori Leslie, MD, provides insight to the incidence and prognosis of follicular lymphoma, highlighting a patient case of refractory disease.

Dr. Leslie on the FDA Approval of Axicabtagene Ciloleucel for Second-Line Relapsed/Refractory LBCL

April 1st 2022

Lori A. Leslie, MD, discusses the FDA approval of axicabtagene ciloleucel for second-line relapsed/refractory large B-cell lymphoma.